Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 8/20 | 0.43 |
| ▸ | GRM6 | O15303 | 5/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 5/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 9/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | GRM8 | O00222 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086083 | 1.00 | GRM2 (0.43) | GRM2GRM6GRM3SLC6A4MAPK1 | |
| SCHEMBL2730057 | 0.84 | GRM2 (0.40) | GRM2GRM6GRM3SLC6A4MAPK1 | |
| SCHEMBL11340978 | 0.82 | MAPK1 (0.37) | GRM2GRM6GRM3MAPK1ALDH1A1 | |
| SCHEMBL76967 | 0.81 | ARG1 (0.38) | GRM2GRM6GRM3SLC6A4MAPK1 | |
| SCHEMBL30746735 | 0.81 | ARG1 (0.38) | GRM2GRM6GRM3SLC6A4MAPK1 | |
| SCHEMBL2524446 | 0.80 | ARG1 (0.34) | GRM2GRM6GRM3SLC6A4MAPK1 | |
| SCHEMBL9729224 | 0.78 | ARG1 (0.33) | GRM2GRM6GRM3MAPK1GRM5 | |
| SCHEMBL28265693 | 0.78 | NFKB1 (0.35) | MAPK1ALDH1A1CYP1A2CYP2C19MEN1 | |
| SCHEMBL1061265 | 0.74 | SLC6A4 (0.42) | GRM2GRM6GRM3SLC6A4GRM5 | |
| SCHEMBL295935 | 0.74 | MAPK1 (0.41) | MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109851635-B | Novel alkylated monophosphine ligand and simple preparation method thereof | 湖北大学 | 2021-03-16 | — | — | CN | claimed |
| CN-112250709-A | Synthesis method of ortho-aryl substituted tertiary phosphine compound | 湖北大学 | 2021-01-22 | — | — | CN | claimed |
| CN-111592567-A | Synthesis method of bidentate phosphine ene ligand | 湖北大学 | 2020-08-28 | — | — | CN | claimed |
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025026470-A1 | PSMA-TARGETED PSMA-PARPI CONJUGATE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江大学 | 2025-02-06 | — | — | WO | disclosed |
| US-12172989-B2 | Histone acetyltransferase (HAT) inhibitor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-12-24 | — | — | US | disclosed |
| WO-2024094152-A1 | SPIRO COMPOUND, AND PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2024-05-10 | — | — | WO | disclosed |
| CN-117986260-A | Spiro compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-05-07 | — | — | CN | disclosed |
| CN-117551037-A | Compounds as succinate dehydrogenase inhibitors and uses thereof | 华东理工大学 | 2024-02-13 | — | — | CN | disclosed |
| CN-117157298-A | Dual-function chimeric heterocyclic compound of interleukin-1 receptor related kinase 4, preparation method, medicinal composition and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-1296949-A2 | PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1294690-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6525069-B1 | Such as N-(t-butyl)-N'-(2-((3-(4-fluorophenyl)methyl)piperi -dinyl)methyl)cyclohexyl)urea; prevention of asthma and other allergic diseases | BRISTOL-MYERS SQUIBB PHARMA CO. | 2003-02-25 | — | — | US | disclosed |
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-24 | — | — | US | disclosed |
| WO-2001098268-A2 | PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001098270-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001098269-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| US-5175146-A | Improved potency; storage stability; nonhydrolyzing; osteoporosis; Paget's disease; hypocalcemic | VICAL, INC. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0135429-B1 | THE SYNTHESIS OF CYCLOPROPANE AMINO ACIDS AND PEPTIDES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | CCR3, CCR1, ACKR3 | GRM2 1293/4885GRM6 1034/4885GRM3 209/4885 |
| US-12172989-B2 | Histone acetyltransferase (HAT) inhibitor and use thereof | EP300, HDAC11, HDAC1 | GRM2 4080/4885GRM6 3826/4885GRM3 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.